Geron finally brings a drug to market as FDA clears Rytelo

More than 30 years after it was first founded, Geron has claimed FDA approval for its first product – myelodysplastic syndromes (MDS) treatment Rytelo.

FDA approves MACE label claim for Lilly’s Trulicity

Ozempic acceleration buoys Novo Nordisk, and threatens Lilly

Novo Nordisk nears EU okay for oral GLP-1 drug Rybelsus afte...

The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus, a key pipeline drug in its type 2 diabetes franchise.

Lilly’s diabetes med Trulicity shrugs off Novo Nordisk chall...

Eli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but the most pleasing aspect for the firm was likely the resilience of its diabetes blockbus